Current Report Filing (8-k)
21 Mayo 2021 - 12:20PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): May 19, 2021
GLOBAL
WHOLEHEALTH PARTNERS CORPORATION
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-56035
|
46-2316220
|
(State
or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification No.)
|
|
2227
Avenida Oliva
San
Clemente, CA
|
92673
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code (714) 392-9752
N/A
(Former name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section
1 - Registrant’s Business and Operations
Item
1.01 Entry into a Material Definitive Agreement.
On
May 19, 2021, Global Wholehealth Partners Corporation (the “Company”) entered into an agreement (“Partnership
Joint Venture Philippines Agreement”) with AAJ Partners Corp. (“AAJPC”) to form a joint venture entity Global
WholeHealth Philippines (“GWP”) through which the Company and AAJPC will build a manufacturing facility in the
Philippines. The Company will supply all of the tests in sheet format made under FDA GMP facility in the United States to GWP and
assist GWP with FDA GMP approved facility in the Philippines. The parties have agreed in the
Partnership Joint Venture Philippines Agreement that the Company will hold 40% ownership and AAJPC will hold 60% ownership.
The
foregoing description of the joint venture does not purport to be completed and is qualified in its entirety by reference to the
Partnership
Joint Venture Philippines Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Section
9 – Financial Statement and Exhibits
Item 9.01 Financial Statements and Exhibits.
|
Exhibit
No.
|
Document
|
Location
|
|
10.1
|
Partnership Joint Venture Philippines Agreement dated May 19,
2021
|
Filed Herewith
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
GLOBAL
WHOLEHEALTH PARTNERS CORPORATION
(Registrant)
|
|
Date:
May 21, 2021
|
By:
/s/ Charles Strongo
Charles Strongo
Chief Executive Officer
|
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
